Biogen Inc. (NASDAQ:BIIB) Given Consensus Rating of “Moderate Buy” by Analysts

Biogen Inc. (NASDAQ:BIIB) has been assigned a consensus rating of “Moderate Buy” from the thirty-three research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $230.1429.

BIIB has been the topic of several recent research reports. HC Wainwright lifted their target price on shares of Biogen from $237.00 to $251.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Bank of America decreased their price target on shares of Biogen from $217.00 to $215.00 and set a “neutral” rating for the company in a research report on Tuesday, July 21st. UBS Group raised their price objective on Biogen from $225.00 to $240.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. HSBC boosted their price objective on Biogen from $165.00 to $175.00 and gave the stock a “reduce” rating in a research note on Thursday, September 10th. Finally, Weiss Ratings downgraded Biogen from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, August 12th.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Bell Investment Advisors Inc purchased a new stake in Biogen during the 2nd quarter worth $27,000. Reflection Asset Management purchased a new position in Biogen in the 4th quarter valued at about $25,000. Root Financial Partners LLC boosted its position in Biogen by 198.4% in the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 123 shares during the last quarter. MV Capital Management Inc. acquired a new stake in shares of Biogen during the fourth quarter valued at about $34,000. Finally, Cassaday & Co Wealth Management LLC acquired a new stake in shares of Biogen during the first quarter valued at about $40,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Biogen Stock Up 1.7%

BIIB opened at $219.07 on Tuesday. Biogen has a 1 year low of $135.39 and a 1 year high of $225.80. The firm has a 50 day moving average price of $211.20 and a 200 day moving average price of $198.54. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.87. The company has a market cap of $32.37 billion, a PE ratio of 38.77, a price-to-earnings-growth ratio of 2.38 and a beta of 0.17.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, beating analysts’ consensus estimates of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The firm had revenue of $2.74 billion for the quarter, compared to analysts’ expectations of $2.46 billion. During the same period in the previous year, the company posted $5.47 earnings per share. Biogen’s revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Sell-side analysts expect that Biogen will post 12.41 earnings per share for the current year.

About Biogen

Biogen Inc is a biotechnology company focused on discovering, developing and commercializing therapies for neurological and neurodegenerative diseases. Founded in 1978, the company is headquartered in Cambridge, Massachusetts, and serves patients and healthcare providers in markets around the world.

Biogen’s portfolio includes treatments for multiple sclerosis, including Tecfidera, Vumerity, Tysabri, Avonex and Plegridy, as well as Spinraza for spinal muscular atrophy, developed in collaboration with Ionis Pharmaceuticals.